

## SUPPLEMENTARY APPENDIX

Rubio-Herrera MA, Mera-Carreiro S, Sánchez-Pernaute A, Ramos-Leví AM. Impact of treatment with GLP1 receptor agonists, liraglutide 3.0 mg and semaglutide 1.0 mg, while on a waiting list for bariatric surgery. Biomedicines 2023

**Table S1. Characteristics of patients according to the decision of abandoning bariatric surgery after 52 weeks of pharmacological therapy with semaglutide 1.0 mg and liraglutide 3.0 mg**

Characteristics	Semaglutide 1.0 mg (n=35)		Liraglutide 3.0 mg (n=67)	
	Abandoning bariatric surgery plans (n=23)	Bariatric Surgery (n=12)	Abandoning bariatric surgery plans (n=47)	Bariatric Surgery (n=20)
Age, years	57.75±6.53	56.25±4.11	52.09±11.16	47.15±11.85
Sex, female (%)	15 (65.2%)	6 (50%)	38 (80.9%)	12 (60.0%)
Baseline Body weight, kg	117.23±13.81	118.80±14.35	112.33±19.36	136.69±40.88
Baseline BMI, kg/m <sup>2</sup>	43.07±4.16	43.01±4.62	42.23±5.69	47.90±11.32
52wk-BMI, kg/m <sup>2</sup>	35.21±5.07	36.55±6.10	34.53±4.83	41.98±8.79
<i>Comorbidities</i>				
Type 2 DM (%)	23 (100%)	12 (100%)	3 (6.4%)	1 (5.0%)
Hypertension (%)	18 (78.3%)	9 (75.0%)	16 (34.0%)	10 (50%)
Dyslipidemia (%)	11 (47.8%)	8 (66.7%)	16 (34.0%)	5 (25.0%)
Obstructive Sleep Apnea (%)	7 (30.4%)	3 (25.0%)	8 (17.0%)	4 (20.0%)
Knee Osteoarthritis (%)	4 (17.4%)	4 (33.3%)	11 (23.4%)	4 (20.0%)
<i>WL(%)</i>				
26-wk	-13.43±6.30	-10.57±3.31	-13.55±5.32	-9.25±3.84
52-wk	-18.33±7.73	-14.01±4.86	-17.51±5.45	-10.78±3.42

**Table S2. Baseline and follow-up laboratory parameters\* according to the type of pharmacological treatment received.**

<b>Laboratory tests</b>	<b>Liraglutide (n=45)</b>		<b>Semaglutide (n=32)</b>	
	<i>Baseline</i>	<i>At 12 months</i>	<i>Baseline</i>	<i>At 12 months</i>
Glycaemia (mg/dL)	100.70 ± 13.89	95.67 ± 9.01	133.97 ± 43.40	111.91 ± 23.80
HbA1c (%)	5.61 ± 0.54	5.50 ± 0.59	6.82 ± 1.48	5.68 ± 0.55
Insulin (μUI/mL)	20.27 ± 14.95	13.86 ± 9.66	26.07 ± 12.76	15.02 ± 8.00
HOMA-IR	5.22 ± 4.09	4.49 ± 6.90	8.26 ± 4.86	4.16 ± 2.46
Total cholesterol, mg/dL	191.55 ± 43.05	180.75 ± 39.83	167.53 ± 47.36	165.22 ± 38.22
Non-HDL cholesterol	141.46 ± 40.55	126.67 ± 36.86	119.68 ± 44.73	115.09 ± 35.85
HDL-c, mg/dL	50.08 ± 12.67	52.35 ± 11.06	47.84 ± 8.99	50.13 ± 11.22
LDL-c, mg/dL	114.17 ± 34.93	104.93 ± 32.15	92.12 ± 36.89	93.65 ± 32.06
Triglycerides, mg/dL	134.40 ± 59.83	108.70 ± 57.00	155.96 ± 99.69	129.84 ± 75.43
AST, U/L	24.28 ± 13.10	21.59 ± 8.36	24.25 ± 9.63	22.53 ± 8.54
ALT, U/L	26.02 ± 19.76	21.50 ± 7.87	26.81 ± 15.22	23.25 ± 11.61
GGT, U/L	34.74 ± 34.83	28.63 ± 26.79	37.87 ± 22.51	28.47 ± 14.36

\*Data available for 77 patients.